Toggle Main Menu Toggle Search

Open Access padlockePrints

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

Lookup NU author(s): Dr Tina Biss, Professor Farhad Kamali


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


© 2019, The Author(s), under exclusive licence to Springer Nature Limited. Studies on the effect of cytochrome P450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P450 4F2 (CYP4F2) polymorphisms on warfarin maintenance dose in children are conflicting. We conducted a systematic review and meta-analysis to evaluate the effect of these polymorphisms on warfarin maintenance dose in children. We searched relevant literature using the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trial libraries without any language restrictions from their inception to 23 July 2017. Dose differences are expressed as standardized mean difference (SMD) or mean difference (MD) with 95% confidence intervals (CI). This review was registered in the PROSPERO prospective register of systematic reviews (CRD42015016172). We included a total of nine studies (745 participants) in the meta-analysis. Patients with CYP2C9 *1/*2, *1/*3, *2/*2, *2/*3, or *3/*3 required a lower warfarin maintenance dose compared with patients with CYP2C9 *1/*1 (SMD = −0.610, 95% CI: −0.802 to −0.419, I2 = 0%). Patients with VKORC1-1639GA or AA required a lower warfarin maintenance dose compared with patients with VKORC1-1639GG (SMD = −0.666, 95% CI: −0.887 to −0.445, I2 = 33%). However, no associations were observed between CYP4F2 polymorphisms and warfarin maintenance dose (MD = 0.005 mg/kg/day, 95% CI: −0.006 to 0.015, I2 = 0%). These results were not affected by a sensitivity analysis. Our meta-analysis provides evidence that CYP2C9 and VKORC1 variant statuses affect warfarin maintenance dose in children, but not CYP4F2.

Publication metadata

Author(s): Takeuchi M, Kobayashi T, Biss T, Kamali F, Vear SI, Ho RH, Bajolle F, Loriot M-A, Shaw K, Carleton BC, Hamberg A-K, Wadelius M, Hirono K, Taguchi M, Wakamiya T, Yanagimachi M, Hirai K, Itoh K, Brandao LR, Ito S

Publication type: Article

Publication status: Published

Journal: Pharmacogenomics Journal

Year: 2020

Volume: 20

Pages: 306-319

Print publication date: 01/04/2020

Online publication date: 01/11/2019

Acceptance date: 16/10/2019

ISSN (print): 1470-269X

ISSN (electronic): 1473-1150

Publisher: Nature Publishing Group


DOI: 10.1038/s41397-019-0117-x

PubMed id: 31673144


Altmetrics provided by Altmetric